Pharmaceutical physician and MHRA-accredited First in Human Principal Investigator with extensive experience leading First-in-Human and early clinical development studies across a broad range of modalities including siRNA therapeutics, monoclonal antibodies, immunology, inflammation, metabolic disease and novel translational medicine programs.
Currently Medical Director at Parexel’s Phase I Clinical Research Unit in London, with responsibility for medical oversight of complex early phase studies including study design, dose escalation, safety governance, PK/PD interpretation, protocol leadership, regulatory interaction and cross-functional collaboration with sponsor clinical pharmacology and translational medicine teams.
Experienced in the conduct of over 100 Phase I studies, including multiple RNA therapeutic programs and complex biomarker-driven translational studies. Particular interests include early clinical development strategy, translational medicine, biomarker integration, exposure-response relationships and novel modality development.
Board Certification (CCT) in Pharmaceutical Medicine (2023). Executive MBA.